A Multi-national, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated for the Prevention of COVID-19 in Healthy Adults Aged 18 Years and Older

Shenzhen Kangtai Biological Products Co., LTD0 sites28,000 target enrollmentMay 2021

ConditionsCOVID-19

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: COVID-19
Sponsor: Shenzhen Kangtai Biological Products Co., LTD
Enrollment: 28000
Primary Endpoint: Incidence density of symptomatic COVID-19 cases
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The study will be a multi-national, endpoint-driven, randomized, double-blind, placebo-controlled, adaptive study in which participating adults will be randomized 1:1 to receive 2 doses of either candidate vaccine or placebo on Day 0 and 28. A total of 28,000 healthy adults aged 18 years and older will be enrolled and followed for efficacy, safety, and immunogenicity evaluations.

Registry

clinicaltrials.gov

Start Date

May 2021

End Date

November 2022

Last Updated

5 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Shenzhen Kangtai Biological Products Co., LTD

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Healthy residents ≥ 18 years at the time of consent, be voluntary and capable of signing the informed consent forms.
•Be able to understand and comply with study requirements/ procedures.
•Participants with negative results of SARS-CoV-2 Realtime-PCR (RT-PCR) detection.
•For females or sex-partners of males at childbearing age: be willing to use birth control for 3 months after the 2nd dose.
•For females of childbearing potential (Pausimenia ≤ 2 years ) must: have a negative urine or blood pregnancy test at screening
•Axillary temperature \< 37.3℃/99.1℉ when screening (Subsequent measurements of temperature should be performed at the same site per participant; temperature measured by other methods should be converted to axillary temperature ).

Exclusion Criteria

•Previous treatments for curing or preventing COVID-19 (including vaccination of various COVID-19 vaccines).
•History of Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) or other coronavirus infections.
•History of allergy to any components of the candidate vaccine or severe allergic reactions to vaccine or medicine (including, but not limited to, allergic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, or local allergic necrosis (Arthus reaction)).
•Positive for HIV detection.
•History or family history of convulsion, epilepsy, encephalopathy, and psychosis.
•Active stage of malignancies, malignancies without adequate treatments, malignancies with potential risk for recurrence during the study.
•Severe or uncontrolled cardiovascular, neurological, blood and lymphatic, kidney, liver, respiratory, metabolic and skeletal diseases.
•Congenital or functional absence of spleen, complete or partial removal of spleen in any case.
•Chronic administration (defined as ≥ 14 days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the 1st vaccination (eg. corticosteroids, ≥ 0.5 mg/kg/day prednisone or equivalent; but, inhaled and topical steroids are allowed).
•Planned administration/administration of a vaccine not foreseen by the study protocol less than 7 days before 1st dose of candidate vaccine for inactivated vaccines or 14 days before 1st dose of candidate vaccine for attenuated live vaccines.

Outcomes

Primary Outcomes

Incidence density of symptomatic COVID-19 cases

Time Frame: 14 days after full vaccination

Incidence density of symptomatic COVID-19 cases occurring from 14 days after full vaccination.

Secondary Outcomes

Incidence of AESI(from the 1st dose through the end of study)
Geometric mean titer of SARS-CoV-2 neutralizing antibody(28 days, 90 days, 180 days and 360 days after full vaccination)
Seroconversion rate of SARS-CoV-2 IgG binding antibody(28 days, 90 days, 180 days and 360 days after full vaccination)
Geometric mean fold increase of SARS-CoV-2 IgG binding antibody(28 days, 90 days, 180 days and 360 days after full vaccination)
Incidence density of COVID-19 moderate cases and above(14 days after full vaccination)
Incidence density of COVID-19 severe cases and above(14 days after full vaccination)
Incidence density of COVID-19 death cases and above(14 days after full vaccination)
Incidence of solicited local adverse events(0-7 days after each vaccination)
Incidence of unsolicited adverse events(0-28 days after each vaccination)
Geometric mean titer of SARS-CoV-2 IgG binding antibody(28 days, 90 days, 180 days and 360 days after full vaccination)
Incidence density of symptomatic COVID-19 cases in different age groups(14 days after full vaccination)
Incidence of solicited general adverse events(0-7 days after each vaccination)
Incidence of SAE(from the 1st dose through the end of study)
Seroconversion rate of SARS-CoV-2 neutralizing antibody(28 days, 90 days, 180 days and 360 days after full vaccination)
Geometric mean fold increase of SARS-CoV-2 neutralizing antibody(28 days, 90 days, 180 days and 360 days after full vaccination)